The state of Michigan currently has 21 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
ETNA-MS Device Validation Study
Recruiting
The overarching goal of this research protocol is to validate the effectiveness of Innodem's ETNA-MS device in informing clinicians on the disability status of Multiple Sclerosis (MS) patients. Effectiveness of the device will be assessed by the level of agreement between the EDSS estimated by the device and the actual scores measured by the neurologist in-person assessments.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Michigan Institute for Neurological Disorders, Farmington Hills, Michigan +1 locations
Conditions: Multiple Sclerosis
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Detroit, Michigan +1 locations
Conditions: Relapsing-Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Recruiting
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Detroit, Michigan
Conditions: Relapse Remitting Multiple Sclerosis
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Recruiting
Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period. Current interventions to improve fall risk have focused on forward walking (FW) and balance training, resulting in small declines in the relative risk for falls with a large degree of variability. Interestingly, motor differences between MS and healthy controls are more pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Wayne State University, Detroit, Michigan
Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Recruiting
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/07/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Multiple Sclerosis, Sleep, Pain
A Pilot Randomized Controlled Trial: CoINTEGRATE
Recruiting
The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions. The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care.
Gender:
All
Ages:
Between 21 years and 65 years
Trial Updated:
09/10/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
PTNS for Female Patients Suffering From Multiple Sclerosis
Recruiting
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of PTNS in treating OAB symptoms in MS patients. The data generated by this study would provide support for a future multi-institutional, randomized prospective trial.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Beaumont Hospital - Royal Oak, Royal Oak, Michigan
Conditions: Multiple Sclerosis, Overactive Bladder
Mechanistic Study of Ocrevus
Recruiting
The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/27/2022
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Multiple Sclerosis
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Recruiting
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/03/2022
Locations: Wayne State University, Detroit, Michigan
Conditions: Multiple Sclerosis, Relapsing-Remitting